miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009;136(1):26–36.
   PubMed Web of Science ®Google Scholar
• Ventura A, MicroRNAs JT. and cancer: short RNAs go a long way. Cell. 2009;136(4):586–591.
   PubMed Web of Science ®Google Scholar
• Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116:1105–1113.
   PubMed Web of Science ®Google Scholar
• Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118:5891–5900.
   PubMed Web of Science ®Google Scholar
• Du L, Subauste MC, DeSevo C, et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012;7:e39167.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee YH, Bae YS. MiR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells. Biochem Biophys Res Commun. 2012;429(3–4):173–179.
   PubMed Web of Science ®Google Scholar
• Xiao W, Yao E, Zheng W, et al. miR-337 can be a key negative regulator in melanoma. Cancer Biol Ther. 2017;18:392–399.
   PubMed Web of Science ®Google Scholar
• Zhang R, Leng H, Huang J, et al. miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7. Diagn Pathol. 2014;9:171.
   PubMed Web of Science ®Google Scholar
• Zhang R, Zheng S, Du Y, et al. Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients. Diagn Pathol. 2014;9:61.
   PubMed Web of Science ®Google Scholar
• Zuo XL, Chen ZQ, Wang JF, et al. miR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2. Am J Cancer Res. 2018;8:662–674.
   PubMed Web of Science ®Google Scholar
• Litvinov IV, Cordeiro B, Fredholm S, et al. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle. 2014;13:2975–2982.
   PubMed Web of Science ®Google Scholar
• Dobbeling U. Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas. Curr Drug Discov Technol. 2007;4(1):24–30.
   PubMedGoogle Scholar
• van der Fits L, Out-Luiting JJ, van Leeuwen MA, et al. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome. J Invest Dermatol. 2012;132:440–447.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13:735–738.
   PubMed Web of Science ®Google Scholar
• Kopp KL, Ralfkiaer U, Gjerdrum LM, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013;12:1939–1947.
   PubMed Web of Science ®Google Scholar
• van Kester MS, Out-Luiting JJ, von Dem Borne PA, et al. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol. 2008;128:1691–1695.
   PubMed Web of Science ®Google Scholar
• Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15:787–793.
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol. 2011;131:1331–1338.
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 2006;20:1759–1766.
   PubMed Web of Science ®Google Scholar
• Kopp KL, Kauczok CS, Lauenborg B, et al. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia. 2010;24:1179–1185.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gjerdrum LMR, Biskup E, et al. Notch 1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2010; blood-2009-12-260216.
   PubMedGoogle Scholar
• Park JK, Doseff AI, Schmittgen TD. MicroRNAs Targeting Caspase-3 and −7 in PANC-1 Cells. Int J Mol Sci. 2018;19:4.
   Web of Science ®Google Scholar
• Cui H, Song R, Wu J, et al. MicroRNA-337 regulates the PI3K/AKT and Wnt/beta-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2. Am J Cancer Res. 2018;8:405–421.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhang N, Ma W, et al. MiR-337-3p promotes chondrocytes proliferation and inhibits apoptosis by regulating PTEN/AKT axis in osteoarthritis. Biomed Pharmacother. 2017;95:1194–1200.
   PubMed Web of Science ®Google Scholar
• Demarez C, Gerard C, Cordi S, et al. MicroRNA-337-3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation. Hepatology. 2018;67:313–327.
   PubMed Web of Science ®Google Scholar
• Zheng L, Jiao W, Mei H, et al. miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14. Oncotarget. 2016;7:40314–40328.
   PubMedGoogle Scholar
• Xiang X, Mei H, Zhao X, et al. miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14. Oncotarget. 2015;6:22452–22466.
   PubMedGoogle Scholar
• Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62:3351–3355.
   PubMed Web of Science ®Google Scholar
• Kim BH, Yi EH, Ye SK. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res. 2016;39(8):1085–1099.
   PubMed Web of Science ®Google Scholar
• Cafferkey C, Novel CI. STAT 3 inhibitors for treating gastric cancer. Expert Opin Investig Drugs. 2016;25(9):1023–1031.
   PubMed Web of Science ®Google Scholar
• Bosch-Barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treat Rev. 2017;58:61–69.
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Litvinov IV, Moreau L, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13:3331–3335.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105.
   PubMed Web of Science ®Google Scholar
• Baigude H, Ahsanullah, Li Z, et al. miR-TRAP: a benchtop chemical biology strategy to identify microRNA targets. Angew Chem Int Ed Engl. 2012;51:5880–5883.
   PubMed Web of Science ®Google Scholar